Your browser is no longer supported. Please, upgrade your browser.
OREX Orexigen Therapeutics, Inc. daily Stock Chart
OREX [NASD]
Orexigen Therapeutics, Inc.
Index- P/E- EPS (ttm)-0.26 Insider Own9.05% Shs Outstand125.21M Perf Week0.42%
Market Cap597.25M Forward P/E- EPS next Y-0.43 Insider Trans-0.44% Shs Float124.31M Perf Month-7.02%
Income-29.90M PEG- EPS next Q-0.16 Inst Own96.20% Short Float27.65% Perf Quarter-38.92%
Sales59.00M P/S10.12 EPS this Y60.00% Inst Trans0.05% Short Ratio12.41 Perf Half Y-24.29%
Book/sh0.10 P/B47.70 EPS next Y15.70% ROA-16.90% Target Price11.33 Perf Year-23.31%
Cash/sh1.51 P/C3.17 EPS next 5Y- ROE-229.20% 52W Range3.11 - 9.37 Perf YTD-21.29%
Dividend- P/FCF20.67 EPS past 5Y28.10% ROI-28.80% 52W High-49.84% Beta2.27
Dividend %- Quick Ratio7.50 Sales past 5Y253.90% Gross Margin- 52W Low51.13% ATR0.23
Employees47 Current Ratio7.60 Sales Q/Q388.90% Oper. Margin-38.60% RSI (14)40.07 Volatility5.76% 5.01%
OptionableYes Debt/Eq6.90 EPS Q/Q39.10% Profit Margin-50.50% Rel Volume0.51 Prev Close4.77
ShortableYes LT Debt/Eq6.90 EarningsAug 06 BMO Payout- Avg Volume2.77M Price4.70
Recom1.70 SMA20-0.48% SMA50-11.93% SMA200-16.98% Volume1,330,853 Change-1.47%
Mar-27-15Reiterated RBC Capital Mkts Outperform $10 → $14
Jan-23-15Initiated RBC Capital Mkts Outperform $10
Jan-10-14Initiated WallachBeth Buy $9
Oct-03-13Initiated Cowen Outperform $10
Sep-21-11Upgrade JMP Securities Mkt Perform → Mkt Outperform $5
Feb-01-11Downgrade JMP Securities Mkt Outperform → Mkt Perform
Feb-01-11Downgrade Canaccord Genuity Buy → Hold
Dec-03-10Downgrade Rodman & Renshaw Mkt Perform → Mkt Underperform
Jul-16-10Reiterated JMP Securities Mkt Outperform $16 → $13
Jul-16-10Downgrade Rodman & Renshaw Mkt Outperform → Mkt Perform
Feb-02-10Initiated Jefferies & Co Buy $12
Jun-24-09Initiated Rodman & Renshaw Mkt Outperform $14
Mar-13-09Reiterated Lazard Capital Mkts Buy $13 → $10
Apr-03-08Initiated Cowen & Co Outperform
Feb-06-08Initiated Lazard Capital Buy
Feb-04-08Reiterated Canaccord Adams Buy $29 → $32
Jan-03-08Initiated JP Morgan Overweight
Oct-03-07Upgrade JMP Securities Mkt Outperform → Strong Buy $26
Jun-07-07Initiated JP Morgan Overweight
Jun-06-07Initiated JMP Securities Mkt Outperform $26
Jul-05-15 02:18PM  Obesity Statistics Take a Wrong Turn in This Latest Study at Motley Fool
Jun-26-15 04:51PM  OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and E
Jun-18-15 09:00AM  Orexigen Therapeutics to Speak at the JMP Securities Life Sciences Conference PR Newswire
Jun-11-15 04:07PM  OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
Jun-05-15 05:24PM  OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
10:20AM  Orexigen, Takeda file suit against Actavis to stop generic diet pill
08:31AM  Orexigen Announces Upcoming Data Presentations from the Open-Label Contrave® Ignite Study at the Annual Meeting of the American Diabetes Association PR Newswire
08:30AM  Orexigen and Takeda File Lawsuit Against Actavis for Infringement of Contrave® Patents PR Newswire
Jun-04-15 11:51AM  5 Stocks Under $10 Set to Soar Higher at TheStreet
May-29-15 05:23PM  OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement
04:36PM  Orexigen's Rocky Partnership Could End in Disaster at Investopedia
May-27-15 04:05PM  Zosano Pharma Appoints Joseph P. Hagan to Board of Directors GlobeNewswire
May-20-15 06:58AM  Orexigen CEO Pledged To Keep Data Secret, But Not From Himself at Forbes
May-15-15 01:04PM  OREXIGEN THERAPEUTICS, INC. Financials
May-14-15 04:41PM  5 Key Takeaways From Orexigen's Earnings at Investopedia
01:51PM  Drugmakers Very Bad Day Doesnt Merit a Single Stock Downgrade at Bloomberg
10:29AM  Did Orexigen Have The Right To File Its Controversial Patent? at Forbes
May-13-15 05:06PM  OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Other Events -15.35%
04:33PM  Macy's and Orexigen are big market movers
02:15PM  Are Problems at Orexigen Still Just Getting Started? at 24/7 Wall St.
01:10PM  Orexigen Slumps as New Contrave Data Comes to Light - Analyst Blog
12:27PM  Orexigen and Takeda Feud Over Cost of a Controversial Diet Drug Trial at The Wall Street Journal
10:56AM  Biotech Stock Roundup: Alexion to Buy Synageva, FDA Panel Backs Vertex's Orkambi - Analyst Blog
10:14AM  Orexigen Therapeutics (OREX) Stock Continues to Sink on Contrave Study Fallout at TheStreet
May-12-15 09:22PM  Tuesday's After-Hours Movers: Vertex Pharmaceuticals, Orexigen Therapeutics And More -13.56%
08:23PM  Takeda Threatens to End Orexigen Partnership After Study Halted at Bloomberg
07:19PM  Orexigen Therapeutics Provides Statement on Termination of the Light Study and Updates on Contrave Collaboration with Takeda Pharmaceuticals PR Newswire
07:13PM  Orexigen Comments On Fallout From Data Release at Forbes
06:45PM  Orexigen Drops as Trial Shows Weight Pill Doesnt Help Heart at Bloomberg
04:25PM  Orexigen Study for Diet Drug Ends Over Premature Data Disclosure at The Wall Street Journal
01:26PM  Orexigen Therapeutics (OREX) Stock Declines After Halting Heart Benefit Tests at TheStreet
01:20PM  Diet Drug Study Crashes And Burns In The Wake Of Leaked Results at Forbes
12:57PM  Orexigen Terminates Required Study for Diet Drug Contrave at The Wall Street Journal
12:30PM  A Top Cardiologist Says A Diet Drug Maker Misled Patients And Investors at Forbes
11:06AM  Heart Benefit For Orexigen Drug Nearly Vanishes With New Data at Forbes
08:30AM  Takeda Pharmaceuticals and Orexigen Therapeutics Announce Termination of the Cardiovascular Outcomes Study (Light Study) of the Obesity Drug Contrave® (naltrexone HCl and bupropion HCl) PR Newswire
May-11-15 08:12PM  10-Q for Orexigen Therapeutics, Inc. at Company Spotlight
02:55PM  Orexigen's Q1 Loss Narrower than Expected, Contrave Grows - Analyst Blog
May-08-15 10:00PM  OREXIGEN 72 HOUR DEADLINE ALERT: Approximately 72 Hours Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors of Deadline in Class Action Lawsuit Against Orexigen Therapeutics, Inc. -- OREX GlobeNewswire
04:01PM  Orexigen Therapeutics to Speak at the Bank of America Merrill Lynch Health Care Conference PR Newswire
02:40PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in Orexigen Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline -- OREX Marketwired
12:33PM  UPCOMING DEADLINE: Levi & Korsinsky, LLP Reminds Shareholders of Orexigen Therapeutics, Inc. of Pendency of Class Action Lawsuit and a Lead Plaintiff Deadline of May 11, 2015 Business Wire
08:30AM  Orexigen Therapeutics Inc Earnings Call scheduled for 8:30 am ET today
08:03AM  Orexigen reports 1Q loss
07:21AM  OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a
07:07AM  Q1 2015 Orexigen Therapeutics Inc Earnings Release - Before Market Open
07:00AM  Orexigen Therapeutics Reports Financial and Business Results for the First Quarter Ended March 31, 2015 PR Newswire
May-07-15 11:02AM  Foresite Capital Betting It All On These Four Healthcare Stocks at Insider Monkey
May-06-15 07:09PM  Orexigen Earnings Preview: 5 Things to Look For at Investopedia
May-05-15 10:30AM  OREX Shareholder Alert: Law Offices of Howard G. Smith Reminds Investors of the Lead Plaintiff Deadline in the Class Action Lawsuit Against Orexigen Therapeutics, Inc. Business Wire
08:41AM  Orexigen Therapeutics to Host First Quarter 2015 Financial Results Conference Call at noodls
08:00AM  Orexigen Therapeutics to Host First Quarter 2015 Financial Results Conference Call PR Newswire
Apr-29-15 04:35PM  OREXIGEN SHAREHOLDERS: Shareholder Rights Law Firm Reminds Investors of the Lead Plaintiff Deadline in the Class Action Lawsuit against Orexigen Therapeutics; Investors Encouraged to Contact Firm Business Wire
03:25PM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Orexigen Therapeutics, Inc. of Pendency of Class Action Lawsuit and a Lead Plaintiff Deadline of May 11, 2015 Business Wire
10:30AM  Glancy Binkow & Goldberg LLP Reminds Investors of the Lead Plaintiff Deadline in the Class Action Lawsuit Against Orexigen Therapeutics, Inc. Business Wire
Apr-27-15 08:00AM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in Orexigen Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline -- OREX GlobeNewswire -5.57%
Apr-24-15 10:00PM  OREXIGEN SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Orexigen Therapeutics, Inc. -- OREX Marketwired
Apr-23-15 06:37PM  Orexigen's Obesity Drug Contrave Faces Generic Threat - Analyst Blog
05:44PM  TRADING ALERT: The Rosen Law Firm Reminds Orexigen Therapeutics, Inc. Investors of the Important May 11, 2015 Deadline in the Class Action Business Wire
04:06PM  OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Apr-22-15 07:41AM  Orexigen Announces Receipt of Paragraph IV Certification Notice at noodls
07:30AM  Orexigen Announces Receipt of Paragraph IV Certification Notice PR Newswire
Apr-21-15 10:39AM  SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notify Investors of Class Action Involving Orexigen Therapeutics, Inc. and a Lead Plaintiff Deadline of May 11, 2015 Business Wire -5.03%
Apr-20-15 10:54AM  Glancy Binkow & Goldberg LLP Reminds Investors of the Lead Plaintiff Deadline in the Class Action Lawsuit Against Orexigen Therapeutics, Inc. Business Wire
Apr-15-15 10:17AM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Orexigen Therapeutics, Inc. of Pendency of Class Action Lawsuit and a Lead Plaintiff Deadline of May 11, 2015 - OREX PR Newswire
Apr-14-15 05:02PM  SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Orexigen Therapeutics, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit Business Wire
Apr-13-15 10:30AM  Law Offices of Howard G. Smith Reminds Investors of Orexigen Therapeutics, Inc. of the May 11, 2015 Deadline Business Wire
Apr-10-15 10:00PM  OREXIGEN SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit against Orexigen Therapeutics, Inc. Business Wire
04:39PM  Orexigen Therapeutics to Speak at the Needham Healthcare Conference at noodls
04:01PM  Orexigen Therapeutics to Speak at the Needham Healthcare Conference PR Newswire
01:45PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on Their Investment in Orexigen Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - OREX PR Newswire
09:00AM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Orexigen Therapeutics, Inc. of Pendency of Class Action Lawsuit and a Lead Plaintiff Deadline of May 11, 2015 -- OREX GlobeNewswire
Apr-08-15 04:31PM  5 stocks to watch at MarketWatch
Apr-06-15 07:33PM  SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in Orexigen Therapeutics, Inc. to Contact Brower Piven Before the Lead Plaintiff Deadline in Class Action Lawsuit -- OREX GlobeNewswire
Apr-03-15 12:42PM  EQUITY ALERT: The Rosen Law Firm Reminds Orexigen Therapeutics, Inc. Investors of Important Deadline in Class Action - OREX GlobeNewswire
Apr-02-15 07:14PM  DEADLINE ALERT: Rigrodsky & Long, P.A. Reminds Shareholders Of Orexigen Therapeutics, Inc. Of Upcoming Deadline Business Wire
02:40PM  Vivus Goes on a Diet: Sales Reps are Cut, but Will FDA Help Save Money? at The Wall Street Journal
Mar-30-15 08:49AM  Orexigen Therapeutics Announces that Tom Cannell has Joined As Chief Commercial Officer at noodls
08:45AM  Orexigen Therapeutics Announces that Tom Cannell has Joined As Chief Commercial Officer PR Newswire
07:09AM  Leerink: Europe Deal Coming For Orexigen Therapeutics
Mar-27-15 10:00PM  OREXIGEN SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Orexigen Therapeutics, Inc. -- OREX GlobeNewswire
05:00PM  Barrack, Rodos & Bacine Has Filed an Investor Class Action Against Orexigen Therapeutics, Inc. GlobeNewswire
03:10PM  Orexigen's Obesity Drug Mysimba Gains European Approval - Analyst Blog
02:04PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in Orexigen Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline -- OREX GlobeNewswire
11:23AM  Cohen Milstein Sellers & Toll PLLC Announces the Investigation of Orexigen Therapeutics, Inc. GlobeNewswire
10:25AM  U.S. stocks on track for big weekly loss at MarketWatch
08:25AM  Ahead of the Bell: Orexigen shares rise
Mar-26-15 08:54PM  Oxford Industries, Orexigen And GameStop Lead Thursday's After-Hours Movers
04:32PM  OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Other Events
03:13PM  Orexigen gets approval to market weight loss drug in Europe
02:22PM  Orexigen's Mysimba Approved in Europe for the Treatment of Obesity PR Newswire
Mar-25-15 01:17PM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of OREXIGEN THERAPEUTICS, INC. of PENDENCY OF CLASS ACTION Lawsuit and a Lead Plaintiff DEADLINE of May 11, 2015 -- OREX GlobeNewswire
11:54AM  OREX Shareholder Alert: Investigation on Behalf of Orexigen Therapeutics, Inc. Investors Announced by Law Offices of Howard G. Smith Business Wire
Mar-24-15 09:35AM  Deadline in Lawsuit for Investors in Orexigen Therapeutics, Inc. (NASDAQ:OREX) Shares Announced by Shareholders Foundation GlobeNewswire
Mar-23-15 11:30AM  SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Orexigen Therapeutics, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit Business Wire
Mar-20-15 10:00PM  OREXIGEN SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Orexigen Therapeutics, Inc. Business Wire -5.39%
09:45PM  IMPORTANT ANNOUNCEMENT: Wolf Haldenstein Adler Freeman & Herz LLP Announces That a Federal Securities Class Action Has Been Filed Against Orexigen Therapeutics, Inc. GlobeNewswire
Mar-18-15 04:54PM  Can Orexigen Win Where Obesity-Drug Rivals Failed? at Investopedia
09:30AM  Zacks Industry Outlook Highlights: Orexigen, MannKind, Amgen, Medivation and Express Scripts - Press Releases
Mar-16-15 02:10PM  INVESTOR ALERT: Investigation of Orexigen Therapeutics, Inc. Announced by Glancy Binkow & Goldberg LLP Business Wire
Orexigen Therapeutics, Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products in the United States. The company offers Contrave for the treatment of obesity. It has a collaboration agreement with Takeda Pharmaceutical Company Limited to develop and commercialize Contrave in Canada and Mexico. Orexigen Therapeutics, Inc. was founded in 2002 and is headquartered in La Jolla, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Booth Mark DChief Commercial OfficerFeb 26Option Exercise1.6650,00083,00053,810Mar 02 05:34 PM
Booth Mark DChief Commercial OfficerFeb 26Sale5.6850,000284,2003,810Mar 02 05:34 PM
Turner Heather DSVP, Gen. Counsel & SecretaryDec 02Option Exercise1.6622,64337,58722,643Dec 04 05:05 PM
Turner Heather DSVP, Gen. Counsel & SecretaryDec 02Sale6.0022,643135,8580Dec 04 05:05 PM
Turner Heather DSVP, Gen. Counsel & SecretaryNov 25Option Exercise1.667,38212,2547,382Nov 26 05:01 PM
Turner Heather DSVP, Gen. Counsel & SecretaryNov 25Sale6.007,38244,2920Nov 26 05:01 PM
Turner Heather DSVP, Gen. Counsel & SecretaryNov 24Option Exercise1.6624,00639,85024,006Nov 26 05:01 PM
Turner Heather DSVP, Gen. Counsel & SecretaryNov 24Sale5.7724,006138,5870Nov 26 05:01 PM
BOCK LOUIS CDirectorNov 18Buy5.587003,905700Nov 20 09:16 AM
BOCK LOUIS CDirectorNov 18Buy5.586253,48727,677Nov 20 09:16 AM
BOCK LOUIS CDirectorNov 12Buy5.5727,052150,54427,052Nov 13 09:27 AM
Turner Heather DVP, Gen. Counsel & SecretarySep 22Option Exercise1.66300,000498,000300,000Sep 22 06:49 PM
Turner Heather DVP, Gen. Counsel & SecretarySep 22Sale4.47300,0001,339,5000Sep 22 06:49 PM
Hagan Joseph PSr. VP, Corporate DevelopmentSep 15Buy4.695,00023,45013,026Sep 15 03:11 PM
NARACHI MICHAELPresident and CEOSep 15Buy4.7850,000239,10058,026Sep 15 02:41 PM